Member Info for crumbs

Do you think there is a possibility the combo will be conducted using a nano-delivery? I did ask Scancell this back when we first saw nano delivery being touted for SCIB2 combo and scancell said no SCIB1 combo will be conducted using Ichor... but wonder if we are close to doing a deal on nano delivery that may have changed hmm

I'm not sure what you have proven apart from you are obsessed with a poster...scancells tech has never been valued AIM puts a value on it without any third party ever valuing it...yet!... thing is AIMs next big challenges are to value a landgrab patent and a possible prestigious win on a CRUK grand challenge with tech development and a proof of concept trial all paid for not by placings or dilution then a possible first commercial deal with BioNtech that will be totally IP enhancing and scancell basically gaining a new approach to using one of our platforms... so plenty to come here yet and that is even before trial data from 3 trials comes in...

Scientific facts are not mugs games...LD wanting to cure 'all' cancer is not a mug's game or even a fantasy when you know she knows what she is doing the SCIB1 swimmer chart is not a game or gameable ... our upcoming trials data will not be a game all late-stage cancer patients in modi1's case probably patients with no further treatment options... if modi 1 does as it could... in 3 targets of the over 10 potential ones it may have an effect on.. 6 quid a share then look cheap very cheap with modi2 coming hot on its heels and the fact we would then know is ImmunoBody Keytruda (PD1's) perfect cheap non toxic partner possibly deliverable without a need of electroporation... so yes 14p is where this sp is at this moment in time ...some may say that is cheap I know I do some may say this is still a very risky punt well it is less risky now the trials are all paid to begin and 2 platforms became 3... So lets get those trials on and see what happens this could well be the biggest thing AIM has ever seen.

Plus this is scancell.... always surprises..think of all the events that have come as surprises grand challenge biontech TCR....now new techs! A nano delivery of Imunobody....what next

Yes indeed the best this year could offer is 50p a win on grand challenge and biontech tie up would set us up nicely all IP enhancing non IP diluting.... unless we get a big deal before it's all going to be about trial results and what they bring meantime I expect our US profile to grow with SCIB1 trial there and probably more patient advocacy tie ups..least there is a strategic plan we can be all clear about now....that did not used to be the case.

Well, we see scancell have a 2 to 3 year plan.. we are to have 3 trials in 5 cancer indications all running next year all producing data relatively fast as in a year of full dosing we get to know where scancell fit... we already know there some potentially big milestones this year.. the patent was one, the official announcement of that next month ought to have an effect as the understanding of what 'landgrab' means sinks in... also makes a deal on moditope possible any time after.... Grand challenge we stand a very good chance of a win on it... from that we get prestige we get a modi3 developed and a proof of concept trial involving Genentech(Roche) working under LD... we also could get an IP enhancing deal with BioNtech anytime though possibly not till early next year once all the lab work is fully done.... the valuations in this field are huge why is Kite pharma worth $9 billion... well they do have data and techs ready to go.. we will be in that position in 2 years time we have now 3 platforms ... to say we cannot reach 6 quid within 2 years is not knowing the market we are in and the potential of our techs... SCIB1 could double Keytrudas melanoma sales that deal if done could alone send our current mcap sp above 6 quids... but that is just one product of one platform... we do not need to hit every target here to be minted but we are looking good for hitting them all and the trials are coming - value that!

Lol like nana has the power to talk the sp to 6 quids err no he does not as only actual progress will do that nana is just showing that what if successful that progress ought to mean in values here and that AIM simply has not valued anything yet as for risk well that is well valued in already despite scancell having one successful trial in the bag ...if pi have doubts about the tech simply sit out the coming trials only they are now coming:)....but no one can say they were not told value potential here if they miss the kinds of rises possible here on potential deal/s

Sense not s new...

Yeah makes s new as fits in with dosing regime and is number one PD1 product in melanoma no doubt the clinics get it for free for trial use too....win win win

BTW Merck have admitted they are pretty much totally focused on Keytruda as their biggest asset... wonder would they even wait for the combo trial to end to make a move... that data will be coming in all through the short trial after all

Seems Merck will be closely watching our combo trial... and a great thing is the competition there is so fierce that they will not be the only ones... great that our tech will be in the hands of the kinds of clinicians and clinics that get notice from both pharma and patient groups and even politicians... in the right place at the right time me thinks... 2 years can seem an age but so much can and will happen in that time and once it is over we get to know exactly where scancell will sit in this nascent immuno revolution... I'm pretty confident that the grand challenge LD leading her peers who are already a powerful part of pharma is a good marker.

Totally agree which is why I wonder what Genentech are thinking more they get to see lol... we do at some stage need to go from 22 staff as our pipeline has such potential even beyond cancer that it will need that lab work and eventual trials to take place... but if a proof of concept which we already have in ImmunoBody is needed on moditope then so be it scancells IP will be awesome by then especially if the IP enhancing BioNtech deal is done by then... it really will be a case of we will become more valuable from a pipeline point of view than our suitors!... how mad will that be :)

I'm sure there is (once proven) future scope for moditope combinations (especially if the safety profile is non-toxic) it is all about getting the right keys for those tenacious cancer locks...its why LD is able to forsee curing many if not all cancers we have enough tools in our pipeline to produce taylor made solutions from early to late stage cancers ... new tools just added with these glycan approaches...

Yeah could be mostly scenario 2 seeing as this a very novel approach, however Genentech are on the scene and it just is not their way of doing things to let novel science they like to slip from their grip they go in as early as possible and take the science all the way to commercial... well if they really love moditope they are going to have make an offer our BOD cannot refuse or they sweat it out with all other interested pharma as scancell are indeed going to prove or otherwise the science in the clinic and fairly soon too!... and results from that trial will be fairly conclusive within a year of full dosing.... now if the science works that puts scancell in one hell of a powerful position if however something goes wrong... and I do not know what as it is already proven to work in human donated blood and humanised mice but well anyways...if it did then we have taken the full risk hit ourselves and will pay the price of whatever AIM deems fit....a risk but a calculated one.

Three ways of looking at it... either 1.pharma are really interested but not offering a deal scancell are comfortable with or 2. they are showing an interest but not offering anything till they know it works or3. scancell themselves are so confident of moditope that they are offering nothing till they have proven it in the clinic .... All we know for sure is scancell themselves are getting on with modi1 trial in 3 targets and getting modi2 trial ready as well....I do not know which of the 3 is closest to the truth possibly a bit of all of them in play... I do know modi1 has gone from 3 trial targets to recently 4 and then back to 3... which tells me something has been going on...I do like to think and do get the impression LD is very confident in the coming results of moditope in trial and she did indeed say it could be as big if not bigger than CI currently are and how big are those! All ip owned by scancell patent landgrab of a whole novel approach :) defo a buy and hold.

RG just forwards mine to CH lol.. not that I have sent many in fact just one asking about nano delivery of SCIBs...Of course we should let CH settle in and to be fair he has a lot to soak up and does seem to be doing that... a full understanding of all immuno techs and the whole emergent market that is growing up on them is no easy task especially as it is so new and the science is moving rapidly as the understanding of the immune system and cancer and the interaction between both becomes clearer and clearer. but still, that's his job now!

Great post TF and I agree... and the thing is Chiplin does do a bit of that but doesn't seem to have rubbed off on his man CH yet..we get the immunotherapy market is just like the internet before it got big... look at how Amgen became Amgen and all kinds of anecdotes from Chippers which I like.. but even more in-depth ones would be good ... The trouble is I'm not sure even they get the immuno market it's Lindy that does nana is quite right it is her that can talk about all the techs out there and do the go compares point out the plusses and minuses... why is Kite pharma worth $9 billion... is it even! Certainly having a CEO who is an expert on the entire field would be a good thing.... but meantime yeah get those vids done explaining where scancells tech fits in the field and therefore the market.

We may get some more patient advocacy action pre modi1 trials too... those are some hard and nasty targets we are going for with some dedicated charities groups determined to overcome those cancers.

That makes perfect sense.. in doing such a deal we lose zero IP gain a new approach and impressive partner plus get some cash and an sp raise which fits in with the 2 year plan of cracking America by getting more high profile and a bigger mcap... a win on grand challenge would be more cream and validation... the one that puzzles me most is not all that and not getting those ImmunoBody combo results in and hopefully moving away from electroporation...that all makes sense but to me it is the involvement of Ira Mellman... are Genentech really going to be sitting on the fence right till modi 1 is turning out data... maybe yes maybe they will have to but it is not how they usually operate especially when their number one immunologist is working under LD on the grand challenge team and already has a good relationship with Sahin of BioNtech... what gives!!?

I agree BioNtech could make a move anytime now they are getting lab data... also with the close relationship with Sahin who I believe is also the number one business decision maker at BioNtech as well as the chief scientist we could be in for more collaborations with them...hopefully, many fruitful conversations happening in Mainz